Regeneron Pharmaceuticals has launched its first corporate venture capital fund, committing $500 million to invest in biotechnology, healthcare, and health technology startups over the next five years. The fund, known as Regeneron Ventures, will allocate $100 million annually and is based in Greenwich, CT. It will be led by former Regeneron executives Michael Aberman and Jay Markowitz, focusing on long-term investments across various therapeutic areas, technologies, and development stages. Additionally, Regeneron's stock has seen a significant increase, rising 4,996% since its IPO.